Tildipirosin

Verify with FDA CVM →

196 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
196
Total Reports
132
Deaths Reported
6730.0%
Death Rate

Active Ingredients

Tildipirosin

Administration Routes

SubcutaneousUnknownParenteralOtherTopicalIntramuscularOral

Species Affected

Cattle 161
Unknown 21
Human 12
Pig 1
Other Deer 1

Most Affected Breeds

Holstein-Friesian also known as Holstein 61
Crossbred Bovine/Cattle 55
Unknown 34
Cattle (unknown) 20
Aberdeen Angus 13
Cattle (other) 5
Mixed (Cattle) 3
Shorthorn (unspecified) 2
Hereford cattle 1
Crossbred Porcine/Pig 1

Most Reported Reactions

Lack of efficacy (bacteria) - NOS 119
DEATH-TREATMENT FAILURE 70
CULTURE/TITER DATA ABNORMAL 63
Death 60
PR-LUNG(S), LESION(S) 39
Vials, Damaged 16
Unclassifiable adverse event 14
Containers, Abnormal 13
Injection site swelling 12
Death by euthanasia 11
Respiratory tract disorder NOS 10
Diarrhoea 10

Outcome Breakdown

Died
132 (79.0%)
Outcome Unknown
15 (9.0%)
Ongoing
9 (5.4%)
Recovered/Normal
9 (5.4%)
Euthanized
2 (1.2%)

Data Summary

Metric Value
Total adverse event reports 196
Reports involving death 132
Case-fatality rate (reported events) 6730.0%
Distinct species in reports 5
Distinct breeds in reports 11
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Tildipirosin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 196 adverse event reports referencing Tildipirosin, including 132 reports in which the animal died — a 6730.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Tildipirosin. Reported administration routes include Subcutaneous, Unknown, Parenteral, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Tildipirosin reports are Cattle (161 reports), Unknown (21 reports), Human (12 reports), with Cattle accounting for the largest share. Within those species, Holstein-Friesian also known as Holstein (61), Crossbred Bovine/Cattle (55), Unknown (34) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Tildipirosin are Lack of efficacy (bacteria) - NOS (119), DEATH-TREATMENT FAILURE (70), CULTURE/TITER DATA ABNORMAL (63), Death (60). Of the 167 reports with a coded outcome, Died is the leading category at 79.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Tildipirosin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial